High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury
Date
2020Journal
American Journal of TransplantationPublisher
Blackwell Publishing LtdType
Article
Metadata
Show full item recordAbstract
The clinical importance of subclinical, early T cell–mediated rejection (Banff TCMR 1A and borderline lesions) remains unclear, due, in part to the fact that histologic lesions used to characterize early TCMR can be nonspecific. Donor-derived cell-free DNA (dd-cfDNA) is an important molecular marker of active graft injury. Over a study period from June 2017 to May 2019, we assessed clinical outcomes in 79 patients diagnosed with TCMR 1A/borderline rejection across 11 US centers with a simultaneous measurement of dd-cfDNA. Forty-two patients had elevated dd-cfDNA (≥0.5%) and 37 patients had low levels (<0.5%). Elevated levels of dd-cfDNA predicted adverse clinical outcomes: among patients with elevated cfDNA, estimated glomerular filtration rate declined by 8.5% (interquartile rate [IQR] −16.22% to −1.39%) (−3.50 mL/min/1.73 m2 IQR −8.00 to −1.00) vs 0% (−4.92%, 4.76%) in low dd-cfDNA patients (P =.004), de novo donor-specific antibody formation was seen in 40% (17/42) vs 2.7% (P <.0001), and future or persistent rejection occurred in 9 of 42 patients (21.4%) vs 0% (P =.003). The use of dd-cfDNA may complement the Banff classification and to risk stratify patients with borderline/TCMR 1A identified on biopsy. Copyright 2020 The Authors.Keyword
biomarkercellular transplantation (non-islet)
clinical research/practice
kidney (allograft) function/dysfunction
kidney failure/injury
monitoring: immune
rejection: T cell mediated (TCMR)
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081281914&doi=10.1111%2fajt.15822&partnerID=40&md5=c16941d0a722866cf8debd3d11f1ffc6; http://hdl.handle.net/10713/12323ae974a485f413a2113503eed53cd6c53
10.1111/ajt.15822
Scopus Count
Collections
Related articles
- Dynamic Response of Donor-Derived Cell-Free DNA Following Treatment of Acute Rejection in Kidney Allografts.
- Authors: Wolf-Doty TK, Mannon RB, Poggio ED, Hinojosa RJ, Hiller D, Bromberg JS, Brennan DC
- Issue date: 2021 Apr 29
- Use of a donor-derived cell-free DNA assay to monitor treatment response in pediatric renal transplant recipients with allograft rejection.
- Authors: Steggerda JA, Pizzo H, Garrison J, Zhang X, Haas M, Kim IK, Jordan SC, Puliyanda DP
- Issue date: 2022 Jun
- The Trifecta Study: Comparing Plasma Levels of Donor-derived Cell-Free DNA with the Molecular Phenotype of Kidney Transplant Biopsies.
- Authors: Halloran PF, Reeve J, Madill-Thomsen KS, Demko Z, Prewett A, Billings P, Trifecta Investigators
- Issue date: 2022 Feb
- Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study.
- Authors: Oellerich M, Shipkova M, Asendorf T, Walson PD, Schauerte V, Mettenmeyer N, Kabakchiev M, Hasche G, Gröne HJ, Friede T, Wieland E, Schwenger V, Schütz E, Beck J
- Issue date: 2019 Nov
- Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study.
- Authors: Bu L, Gupta G, Pai A, Anand S, Stites E, Moinuddin I, Bowers V, Jain P, Axelrod DA, Weir MR, Wolf-Doty TK, Zeng J, Tian W, Qu K, Woodward R, Dholakia S, De Golovine A, Bromberg JS, Murad H, Alhamad T
- Issue date: 2022 Apr